65,437 trials
Anal Cancer · Rectal Cancer
Primary: Percentage of Participants With Best Overall Response According to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 — 2.8 percentage of participants
SARS-CoV2 Infection
Primary: Dental Health Care Worker (DHCW) Willingness to Participate in the Study — 10 Participants
Substance Abuse, Intravenous · HIV · Heroin Dependence
Primary: People Initiated Into Injection Drug Use — 2.05; 3.26 People initiated — p=0.35
Postoperative Delirium · Sleep · Anesthesia
Primary: Incidence of Delirium — 5; 16 Participants — p=0.029
Postpartum Hemorrhage
Primary: Number of Participants With Postpartum Hemorrhage (PPH) — 409; 399; 111; 125 Participants — p=0.33
Diabetes Mellitus, Type 2
Primary: Change From Baseline in Total Clamp Disposition Index (cDI) — 1.9; 1.1; 0.0 pmol*m-2*L*min-2*kg-1 — p=<0.001
Inflammatory Acne
Primary: Total Inflammatory Lesion Count — 18.55; 24.51; 20.04 lesions
Hemostasis
Primary: Clot Degradation at 24 Hours Post-operatively — 0.65; 0.88; 0.78; 0.46 microns per hour
Advanced Renal Cell Carcinoma · Metastatic Renal Cell Carcinoma
Primary: Progression-Free Survival (PFS) as Assessed by the Independent Radiology Committee (IRC) — 9.33; 9.17 months — p=0.6528
Acute Myeloid Leukemia (AML) · Cancer
Primary: Percentage of Participants With Complete Remission or Complete Remission With Incomplete Blood Count Recovery (CR + CRi) — 70.0; 63.3 percentage of participants
Hypertension · Chronic Kidney Diseases
Primary: Change in 24-hour Mean Arterial Pressure (MAP) — 1.4 mmHg
Precancerous Condition
Primary: Patient Satisfaction in the 2 Interventions — 11.79; 11.68 score on a scale — p=> 0.05
Pregnancy Related
Primary: Device Ease of Use — 72.8; 75.1 score on a scale — p=0.64
Body Fat
Primary: Number of Participants Who's Abdominal Tissue Showed Necrosis or Inflammatory Immune Cell Response — 10; 0 Participants
Opioid Use Disorder
Primary: Percentage of Participants Fully-Adherent to Buprenorphine — 6; 3 Participants